MARKET

BCRX

BCRX

BioCryst Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

14.92
-0.45
-2.93%
After Hours: 15.03 +0.11 +0.74% 19:17 09/24 EDT
OPEN
15.25
PREV CLOSE
15.37
HIGH
15.30
LOW
14.91
VOLUME
2.12M
TURNOVER
--
52 WEEK HIGH
18.48
52 WEEK LOW
3.300
MARKET CAP
2.67B
P/E (TTM)
-12.3449
1D
5D
1M
3M
1Y
5Y
Biondo Focus Fund Buys NVIDIA Corp, BioCryst Pharmaceuticals Inc, Teladoc Health Inc, Sells ...
GuruFocus News · 3d ago
BioCryst to Present at 2021 Cantor Virtual Healthcare Conference
BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the 2021 Cantor Virtual Healthcare Conference on Tuesday, September 28, 2021 at 2:00 p.m. ET.
GlobeNewswire · 4d ago
BRIEF-BioCryst To Increase Size Of Board From Ten To Eleven Directors
reuters.com · 5d ago
NICE Recommends BioCryst's Hereditary Angioedema Med
Benzinga · 09/16 15:50
BioCryst Scores UK Regulatory Recommendation for Hereditary Angioedema Drug Orladeyo
MT Newswires · 09/16 04:13
BRIEF-BioCryst Says NICE Recommends Orladeyo (Berotralstat), First Oral, Once-Daily Therapy, To Prevent Attacks In HAE Patients In UK
reuters.com · 09/16 00:25
NICE Recommends BioCryst’s ORLADEYO® (berotralstat), the First Oral, Once-daily Therapy, to Prevent Attacks in HAE Patients in the UK
RESEARCH TRIANGLE PARK, N.C., Sept. 15, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the United Kingdom’s (UK) National Institute for Health and Care Excellence (NICE) has recommended ORLADEYO® (berotralstat) ...
GlobeNewswire · 09/16 00:20
Sector Update: Health Care
MT Newswires · 09/15 15:40
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BCRX. Analyze the recent business situations of BioCryst Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 12 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BCRX stock price target is 21.27 with a high estimate of 30.00 and a low estimate of 16.00.
EPS
Institutional Holdings
Institutions: 264
Institutional Holdings: 113.09M
% Owned: 63.23%
Shares Outstanding: 178.87M
TypeInstitutionsShares
Increased
58
10.08M
New
42
6.65M
Decreased
59
12.06M
Sold Out
36
4.62M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.13%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Non-Executive Chairman/Independent Director
Robert Ingram
Chief Executive Officer/President/Director
Jon Stonehouse
Chief Financial Officer
Anthony Doyle
Other/IR Contact Officer
John Bluth
Other
Yarlagadda Babu
Other
Charles Gayer
Other
William Sheridan
Other
Helen Thackray
Secretary
Alane Barnes
Director
Steven Galson
Director
Amy Mckee
Director
Vincent Milano
Independent Director
George Abercrombie
Independent Director
Stephen Aselage
Independent Director
Theresa Heggie
Independent Director
Nancy Hutson
Independent Director
Kenneth Lee
Independent Director
Alan Levin
No Data
  • All
  • Financials
  • Insiders
More
About BCRX
BioCryst Pharmaceuticals, Inc. (BioCryst) is a commercial-stage biotechnology company that discovers small-molecule medicines. The Company focus on oral treatments for rare diseases in which unmet medical needs exist and an enzyme plays the key role in the biological pathway of the disease. ORLADEYO (berotralstat) is an oral, once-daily therapy that is approved in the United States, the European Union, Japan, and the United Kingdom for the prevention of hereditary angioedema (HAE) attacks in adults and pediatric patients 12 years and older. BioCryst has several ongoing development programs, including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases; BCX9250, an activin receptor-like kinase-2 (ALK-2) inhibitor for the treatment of fibrodysplasia ossificans progressiva, and Galidesivir, an antiviral drug for Marburg virus disease and Yellow Fever. RAPIVAB (peramivir injection) is a viral neuraminidase inhibitor for the treatment of influenza.

Webull offers kinds of BioCryst Pharmaceuticals, Inc. stock information, including NASDAQ:BCRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BCRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BCRX stock methods without spending real money on the virtual paper trading platform.